Yoko Kataoka

Dr. Yoko Kataoka


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2022 in Cancer Science
Verified
Journal Article
Open access
YKYo Kawaguchi
Yo Kawaguchi
YOYasuhiko Ohshio
Yasuhiko Ohshio
AWAtsuko Watanabe
Atsuko Watanabe
TSTakuya Shiratori
Takuya Shiratori
KOKeigo Okamoto
Keigo Okamoto
JHJun Hanaoka
Jun Hanaoka
In lung cancer, tumor‐associated macrophages (TAMs), especially M2‐like TAMs, represent the main tumor progression components in the tumor microenvironment (TME). Therefore, M2‐like TAMs may serve as a therapeutic target. The purpose of this study was to investigate the effect of M2‐like TAM depletion in the TME on tumor growth and chemotherapy response in lung cancer. The levels of secreted monocyte chemoattractant protein (MCP‐1) and prostaglandin E2 (PGE2) in the supernatants of lung cancer cell lines A549 and LLC were evaluated via ELISA. Cell migration assays were performed to assess the recruitment ability of macrophage cell lines THP‐1 and J774‐1 cells. Differentiation of macrophages was assessed via flow cytometry. Immunohistochemical staining was performed to visualize M2‐like TAMs in transplanted lung cancer in mouse. We used the COX‐2 inhibitor nimesulide to inhibit the secretion of MCP‐1 and PGE2, which promotes macrophage migration and M2‐like differentiation. Nimesulide treatment decreased the secretion of MCP‐1 and PGE2 from lung cancer cells. Nimesulide treatment suppressed the migration of macrophages by blocking MCP‐1. Lung cancer supernatant induced the differentiation of macrophages toward the M2‐like phenotype, and nimesulide treatment inhibited M2‐like differentiation by blocking MCP‐1 and PGE2. In the lung cancer mouse model, treatment with nimesulide depleted M2‐like TAMs in the TME and enhanced the tumor inhibitory effect of cisplatin. Our results indicated that blocking the secretion of MCP‐1 and PGE2 from tumor cells depleted M2‐like TAMs in the TME and the combination therapy with cisplatin considerably suppressed tumor growth in the LLC mouse model.

30 August 2023 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
KTKoji Teramoto
Koji Teramoto
TITomoyuki Igarashi
Tomoyuki Igarashi
YKYoko Kataoka
Yoko Kataoka
MIMitsuaki Ishida
Mitsuaki Ishida
JHJun Hanaoka
Jun Hanaoka
YDYataro Daigo
Yataro Daigo
Programmed cell death-ligand 1 (PD-L1) on tumor cells can be degraded to soluble form (sPD-L1) and enter circulation, however, the clinical significances of sPD-L1 in peripheral blood remains to be elucidated in non-small-cell lung cancer (NSCLC). We monitored plasma sPD-L1 levels during perioperative periods and evaluated PD-L1-positive cells in tumor tissues in patients with operable NSCLC. Then the correlation between preoperative plasma sPD-L1 levels and relapse-free survival (RFS) was analyzed retrospectively. In patients who underwent radical surgery (n = 61), plasma sPD-L1 levels (median; 63.5 pg/mL) significantly increased 1 month after surgery (72.2 pg/mL, P < 0.001). The combined score of PD-L1-positive cells including tumor cells and tumor-associated macrophages (TAMs) was significantly associated with preoperative plasma sPD-L1 levels. In patients with high levels of preoperative plasma sPD-L1, the probability of 5-year RFS was significantly poor for patients with low PD-L1 expression intensity of tumor cells (tcPD-L1) compared with those with high tcPD-L1 (33.3% vs. 87.5%, respectively, P = 0.016; 95% CI, 0.013–0.964). In former group, PD-L1-positive TAMs were markedly infiltrating compared with those from latter group (246.4 vs. 76.6 counts/mm2, respectively, P = 0.003). In NSCLC, plasma sPD-L1 can reflect the accumulation of PD-L1-posotive TAMs, not just PD-L1-positive tumor cells. In patients with high levels of preoperative plasma sPD-L1, the prognoses after surgery depends on which PD-L1-positive cells, tumor cells or TAMs, are the primary source of the sPD-L1. Thus, measuring both plasma sPD-L1 levels and PD-L1 expression status of tumor cells and TAMs is of benefit for assessment of postoperative prognosis in operable NSCLC.

22 March 2019 in General Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
YKYoko Kataoka
Yoko Kataoka
TITomoyuki Igarashi
Tomoyuki Igarashi
YOYasuhiko Ohshio
Yasuhiko Ohshio
TFTakuya Fujita
Takuya Fujita
JHJun Hanaoka
Jun Hanaoka

5 June 2024 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
YKYoko Kataoka
Yoko Kataoka
TFTakuya Fujita
Takuya Fujita
JHJun Hanaoka
Jun Hanaoka
There have rarely been reports on the neoplastic transformation in other organs during immunotherapy for lung cancer. We report the case of a 71-year-old man who was diagnosed with advanced pulmonary adenocarcinoma and a thyroid tumor. The patient responded to chemoradiotherapy but developed a recurrence of pulmonary metastasis. Therefore, nivolumab was started, and a complete response for pulmonary metastasis was achieved. After 32 nivolumab cycles, he experienced neck pain, and the thyroid tumor grew rapidly. Histological examination revealed anaplastic thyroid carcinoma. Although rare, immunotherapy for lung cancer has the potential to induce neoplastic transformation in other organs.

1 January 2015 in The Journal of the Japanese Association for Chest Surgery
Verified
Journal Article
Open access
MHMasayuki Hashimoto
Masayuki Hashimoto
JHJun Hanaoka
Jun Hanaoka
YOYasuhiko Oshio
Yasuhiko Oshio
TITomoyuki Igarashi
Tomoyuki Igarashi
YKYoko Kataoka
Yoko Kataoka
KHKazuki Hayashi
Kazuki Hayashi

1 July 2022 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
YKYoko Kataoka
Yoko Kataoka
TFTakuya Fujita
Takuya Fujita
JHJun Hanaoka
Jun Hanaoka